Hello??!! This drug just failed a Phase I trial, so what makes you think it will do any better for something it is LESS suited for. Drug candidates dug up from the graveyard are cheap to trial, but rarely have a pulse.
NDL is way too expensive right now. My valuation model suggests fair value at 10 - 12 cents.
- Forums
- ASX - By Stock
- NDL
- research
research , page-8
-
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)